info: Express server listening on port 9801
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m352ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m10ms[0m
[90mGET /signout [32m200 [90m119ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m130ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m146ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET / [32m200 [90m33ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m123ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m80ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m111ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m73ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m150ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m823ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/832a6abb-726d-b40f-8296-470ad5330121 [32m200 [90m8ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m157ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET /signout [32m200 [90m82ms - 5.77kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m53ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m159ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m57ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m133ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m6ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m129ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m154ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET / [32m200 [90m34ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m133ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m130ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m61ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m145ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m469ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/7873c6be-2193-b51d-b459-3738a681ed46 [32m200 [90m6ms[0m
[90mGET / [32m200 [90m31ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m104ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m4ms[0m
[90mGET /signout [32m200 [90m123ms - 5.78kb[0m
[90mPOST /signin [32m200 [90m65ms - 5.78kb[0m
[90mPOST /signup [32m200 [90m788ms - 5.8kb[0m
[90mGET /validate/b127e9f2485f89703c7d54a1409fa3e687b3b1afe78ef3c9754d2752e3fc764f [32m200 [90m39ms - 4.13kb[0m
[90mPOST /validate [32m200 [90m147ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m6ms[0m
[90mGET / [32m200 [90m59ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m115ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET /ajax/dashboard.html [33m404 [90m1ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m166ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET / [32m200 [90m31ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m106ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET / [32m200 [90m32ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m157ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET /signout [32m200 [90m94ms - 5.77kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m76ms - 5.77kb[0m
[90mGET / [32m200 [90m42ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m60ms - 5.77kb[0m
[90mGET /validate/b127e9f2485f89703c7d54a1409fa3e687b3b1afe78ef3c9754d2752e3fc764f [32m200 [90m40ms - 4.13kb[0m
[90mPOST /validate [32m200 [90m49ms - 4.08kb[0m
[90mGET / [32m200 [90m31ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m58ms - 5.77kb[0m
[90mGET / [32m200 [90m54ms - 3kb[0m
[90mGET /signin [32m200 [90m72ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m126ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m1236ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/969c5e3e-117c-1e43-1143-27d3a0c309fd [32m200 [90m9ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m794ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/20b03579-daf6-401e-da6b-816bf371b8e6 [32m200 [90m8ms[0m
[90mGET / [32m200 [90m54ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m117ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET / [32m200 [90m33ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m105ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET /ajax/dashboard.html [33m404 [90m0ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m149ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET /signout [32m200 [90m94ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m164ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m4ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m1162ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/095ebc52-1bae-f370-5527-58a700057d9d [32m200 [90m11ms[0m
[90mPOST /signin [32m200 [90m122ms - 9.83kb[0m
[90mPOST /signin [32m200 [90m143ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m511ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/e83d0278-7839-5d49-b92e-0670b4123a9d [32m200 [90m4ms[0m
[90mGET /signin [32m200 [90m68ms - 5.77kb[0m
[90mGET /favicon.ico [33m404 [90m0ms[0m
[90mPOST /signin [32m200 [90m158ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m615ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/322ae7df-bc52-597a-9361-b050107963ac [32m200 [90m4ms[0m
[90mPOST /signin [32m200 [90m122ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
Headers.cookies _ga=GA1.1.523500631.1406052092; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUser_id=1000002; ctcUsername=GOPI; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.523500631.1406052092; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUser_id=1000002; ctcUsername=GOPI; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m157ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m803ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/341431cb-e9ae-d217-5bcd-575c8f89528e [32m200 [90m4ms[0m
[90mGET /signin [32m200 [90m62ms - 5.77kb[0m
[90mGET /favicon.ico [33m404 [90m0ms[0m
[90mGET /favicon.ico [33m404 [90m1ms[0m
[90mPOST /signin [32m200 [90m100ms - 5.78kb[0m
[90mPOST /signin [32m200 [90m113ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m581ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/bdbed810-fd93-6cd9-70af-cb1854cac6a2 [32m200 [90m5ms[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m158ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET /signout [32m200 [90m81ms - 5.77kb[0m
Headers.cookies ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m68ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m163ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m522ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/965bcfcb-f54f-60a5-93db-b687f8a78cbc [32m200 [90m5ms[0m
Headers.cookies ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72; ctcUsername=GOPI; ctcUser_id=1000002
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m121ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m571ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/bfda4591-8164-1837-4135-be10d38636ee [32m200 [90m5ms[0m
[90mPOST /signin [32m200 [90m159ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m1003ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/374e9a7a-6da5-7997-11c9-9e10590549f7 [32m200 [90m4ms[0m
[90mPOST /signin [32m200 [90m121ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET / [32m200 [90m27ms - 3kb[0m
[90mGET / [32m200 [90m27ms - 3kb[0m
[90mGET /signout [32m200 [90m124ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m121ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m803ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/3b63f821-3c0f-2fde-c5dd-5115c320e5bb [32m200 [90m5ms[0m
[90mPOST /signup [32m200 [90m80ms - 5.79kb[0m
[90mPOST /signin [32m200 [90m143ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m4ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m969ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/9c5ce8fa-c852-e607-5181-e9047d3da015 [32m200 [90m4ms[0m
[90mPOST /signin [32m200 [90m138ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m4ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m815ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/acc0ec59-6ce3-78e9-8da5-903b2ad99370 [32m200 [90m5ms[0m
[90mGET / [32m200 [90m34ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m111ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET / [32m200 [90m29ms - 3kb[0m
[90mGET /signout [32m200 [90m121ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m121ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET / [32m200 [90m37ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m129ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET /signout [32m200 [90m105ms - 5.77kb[0m
[90mPOST /signin [32m200 [90m343ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m6ms[0m
-----------------------------  Response ---------------------------------
{ status: 200, message: 'Success' }
--------------------------  Response END ---------------------------------
[90mPOST /search [32m200 [90m1191ms[0m
-----------------------------  Response ---------------------------------
[ { nct_id: 'NCT00054275',
    conditions: [ 'Breast Cancer' ],
    overall_status: 'Completed',
    summary: 'RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary\n      for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells\n      from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more\n      tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in\n      treating patients who have stage IV or recurrent breast cancer.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00116675',
    conditions: [ 'Warts' ],
    overall_status: 'Completed',
    summary: 'The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of\n      three different strengths of resiquimod gel applied to common wart(s) three times a week for\n      four weeks.\n\n      A second purpose is to evaluate the safety of the drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00141375',
    conditions: [ 'Neuropathic Pain' ],
    overall_status: 'Completed',
    summary: 'To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain\n      after spinal cord injury.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00189475',
    conditions: [ 'Upper Respiratory Infection' ],
    overall_status: 'Completed',
    summary: 'Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for\n      the treatment of  viral-induced upper respiratory infection in healthy adults aged 18-50\n      years.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'Yes' },
  { nct_id: 'NCT00232375',
    conditions: [ 'GAD Ab Positive Clinically Type 2 Diabetic Patients' ],
    overall_status: 'Completed',
    summary: 'We tested the hypothesis that insulin therapy rather than sulfonylurea (SU) treatment has a\n      preferable outcome to reverse or preserve beta cell function in the patients with diabetes\n      that is called slowly progressive insulin-dependent (type 1) diabetes (SPIDDM) or latent\n      autoimmune diabetes in adult (LADA).',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00293475',
    conditions: 
     [ 'Primary Central Nervous System Lymphoma',
       'Brain and Central Nervous System Tumors',
       'Lymphoma' ],
    overall_status: 'Recruiting',
    summary: 'RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different\n      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells\n      and help kill them or carry cancer-killing substances to them. Chemotherapy drugs such as\n      methotrexate, carboplatin, and cytarabine, work in different ways to stop the growth of\n      cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective\n      drugs, such as sodium thiosulfate, may protect normal cells from the side effects of\n      chemotherapy. Osmotic blood-brain barrier disruption uses mannitol, to open tight junctions\n      in the blood vessels in the brain and allow methotrexate and carboplatin to be carried to\n      tumor. Giving rituximab together with blood-brain barrier disruption and methotrexate-based\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: This phase I/II trial is studying the side effects and best dose of carboplatin\n      when given together with rituximab and methotrexate with blood-brain barrier disruption and\n      delayed  sodium thiosulfate chemoprotection to see how well they work in treating patients\n      with newly diagnosed primary central nervous system lymphoma.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00387075',
    conditions: [ 'Parkinson Disease' ],
    overall_status: 'Active, not recruiting',
    summary: 'This study is designed as a prospective cohort study to test the strategy of combining two\n      biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug,\n      [123I]Î²-CIT , in a population of first-degree relatives of PD patients as a tool to\n      establish an \'at risk\' Parkinson disease cohort without motor symptoms of PD.  First-degree\n      relatives of PD will be recruited through PD research sites and national foundations to\n      participate in this study. In addition, first degree relatives of PD patients will be\n      recruited directly through advertising.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00652275',
    conditions: [ 'Malaria' ],
    overall_status: 'Recruiting',
    summary: 'This study will be the fourth time that the candidate malaria vaccine Merozoite Surface\n      Protein - long synthetic chain, will be tested in malaria endemic populations.in the\n      past,once tested in adults and twice in children proved to be safe in all three occasions\n      for this phase IIb study in children to proceed.  This study will include children who will\n      be randomly allocated to either receive the malaria vaccine adjuvanted with Aluminium\n      Hydroxide or the Verorab control. Each participant will receive 3 immunizations, without the\n      clinical investigators or the participants themselves knowing what has been given. They will\n      then be followed-up for immediate reactions to vaccination, extended safety profile and\n      immunological response associated with protection from malaria. These children will be\n      followed up for over a longer term of two years. Blood will be taken to evaluate the\n      biological safety parameters and also the immune responses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00788775',
    conditions: [ 'Mucosal Lentiginous Melanoma', 'Acral Melanoma', 'Melanoma' ],
    overall_status: 'Active, not recruiting',
    summary: 'The purpose of this research study is to evaluate how effective nilotinib is in treating\n      acral, mucosal, or melanoma arising from sun damaged skin which has spread and was not found\n      to respond to treatment with another Tyrosine Kinase Inhibitor (including but not limited to\n      imatinib mesylate, sunitinib or dasatinib treatment)or was not tolerated.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT00914875',
    conditions: [ 'Laparoscopic Cholecystectomy' ],
    overall_status: 'Completed',
    summary: 'double blind study of kidney function of two groups of adult patients submitted to\n      laparoscopic cholecystectomy and analgesia from tramadol associated to dipyrone or ketorolac',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT00973375',
    conditions: [ 'Drug Eluting Stent' ],
    overall_status: 'Recruiting',
    summary: 'The purpose of this study is to investigate if there is any different follow-up results by\n      angiography and IVUS between two different drug-eluting stents after implanted\n      simultaneously in same individuals.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01065675',
    conditions: [ 'Medication Reconciliation', 'Emergency Department' ],
    overall_status: 'Terminated',
    summary: 'Up to 50% of medication errors and 20% of adverse drug reactions (ADRs) in the hospital\n      setting are estimated to be related to communication issues regarding patient medications at\n      various transition points of care from admission to discharge.  The Joint Commission (TJC)\n      requires accurate and complete medication reconciliation occur at each transition point\n      throughout hospitalization.  Evidence from NQF demonstrates pharmacists (RPh) are the most\n      effective medication management team leaders in the implementation of medication management\n      practices and design of medication error reduction strategies; medication reconciliation is\n      one of the five safety objectives pharmacists are recommended to lead.  In addition, the\n      Massachusetts Coalition for the Prevention of Medical Errors states strong evidence supports\n      the use of pharmacy technicians (CPhT) in conjunction with pharmacists in completing\n      accurate medication histories.\n\n      WMC nurses (RN) currently are involved in the medication reconciliation process.  In 2009, a\n      Medication Use Evaluation (MUE) of Medication Reconciliation Accuracy found a 67% medication\n      error rate on admission determined by comparing the nurse-obtained medication history to the\n      pharmacist-obtained medication history.  The number of home medications identified by the\n      pharmacist compared to the nurse was 411 versus 312 (p<0.0001).  The total percentage of\n      medication errors prevented by the pharmacist was 66.2.  Using the VA Healthcare Failure\n      Mode Effects Analysis - HFMEAâ„¢ Hazard Scoring Matrix, 3 independent pharmacist reviewers\n      found that 18% of patients interviewed had a score greater than 7, and 3 patients had a\n      score of 12 (major/probable), if the discrepancies would not have been identified and\n      corrected by the pharmacist conducting the admission medication reconciliation audit.  The\n      same patients\' discharge medication reconciliation and discharge medication lists were\n      retrospectively reviewed for the MUE, and the total percentage of patients with medication\n      errors on discharge was 43%.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01107275',
    conditions: [ 'Rabies Prevention' ],
    overall_status: 'Completed',
    summary: '700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to\n      receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose\n      of 0.1mL into the skin in the deltoid region. In a subset of 100 children blood was taken\n      for rabies virus neutralizing antibody determination on day 49. All subjects were randomized\n      to receive 2 booster doses (the recommended vaccination schedule for pre-immunized\n      individuals in case of an exposure) on days 0 and 3, one, three or five years later. Blood\n      was taken before and after booster for up to one year.Safety and tolerability of the vaccine\n      was assessed and persistence of immune response up to 1 year after the booster doses.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01398475',
    conditions: [ 'Chronic Inflammatory Disorder', 'Arthritis, Rheumatoid' ],
    overall_status: 'Completed',
    summary: 'The purpose of this trial is to assess the effect of three formulations on the relative\n      bioavailability of LY3009104.  Subjects will receive single dose of LY3009104 on 4 separate\n      occasions with and without food.  Safety evaluation and serial Pharmacokinetic (PK) samples\n      will be collected during each treatment period.  Approximately 5-7 days of washout period\n      between each treatment and a follow-up visit will occur approximately 5 to 7 days after the\n      last dose of study drug.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01417975',
    conditions: [ 'Cancer' ],
    overall_status: 'Recruiting',
    summary: 'Female and male smokers will complete questionnaires and smoking behavior will be examined.\n      After abstaining from smoking for approximately 18 hours, they will be randomized to a\n      moderate intensity exercise groups or passive sitting group.  Smoking satisfaction and\n      smoking behavior will be assessed following treatment.\n\n      The hypotheses detailed below are specific to the randomization of participants into the\n      following 2 groups:\n\n        1. Moderate exercise (Experimental condition; MEG)\n\n        2. Passive sitting (Attention control condition; PSG)\n\n      Hypothesis 1: A bout of moderate intensity exercise will be associated with decreased\n      smoking satisfaction after a temporary period of abstinence compared to a control condition.\n\n      Hypothesis 2: Smoking topographic measures will mediate the relationship between a bout of\n      moderate intensity exercise and smoking satisfaction.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01477775',
    conditions: [ 'Acute Coronary Syndrome', 'Coronary Angioplasty' ],
    overall_status: 'Recruiting',
    summary: 'A subset of patients recruited in the main MATRIX study will be randomized after\n      intervention but before discharge to standard of care (the treating physician will decide\n      which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach\n      based on an algorithm which integrates phenotypic information, including but not limited to\n      residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.',
    primary_outcomes: [ [Object], [Object] ],
    secondary_outcomes: 
     [ [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object],
       [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01502475',
    conditions: [ 'Alternative Medicine', 'Attitudes', 'Beliefs', 'Veterans' ],
    overall_status: 'Recruiting',
    summary: 'In this protocol, the investigators proposed to assess the Complementary Alternative\n      Medicine (CAM) usage patterns in a Veteran population using a CAM survey developed by Dr.\n      Hernandez and colleagues.  This survey, the Complementary, Alternative and Conventional\n      Medicines Attitudes Scale (CACMAS), is a brief, self-report questionnaire that assesses\n      medical use patterns, as well as attitudes about medical treatment and the relationship\n      among these.    The CACMAS will assess the potential role of individual beliefs and\n      attitudes towards complementary and conventional medicine usage patterns, and possibly\n      indicate how this scale might be used to predict optimal treatment offerings for a\n      particular population given attitudes about medical treatments.',
    primary_outcomes: [],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT01519375',
    conditions: 
     [ 'Osteoarthritis',
       'Rheumatoid Arthritis',
       'Ankylosing Spondylitis' ],
    overall_status: 'Completed',
    summary: 'The primary objective of this cross-sectional observational real life study is to\n      investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID\n      associated GI Ulcers to patients prescribed a NSAID. Patients included have  Osteoarthritis,\n      Rheumatoid Arthritis or Ankylosing Spondylitis. Adherence will be assessed by patient\n      questionnaires.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object] ],
    clinical_results: 'No' },
  { nct_id: 'NCT01679275',
    conditions: [ 'Heart Defects, Congenital' ],
    overall_status: 'Recruiting',
    summary: 'Congenital heart disease with need for early surgery in newborns is associated with an\n      increased incidence in global impairment in development. The causes of these late adverse\n      neurologic outcomes are multifactoral and include both fixed (or patient-specific factors)\n      and modifiable factors. They relate to both the mechanism of central nervous system injury\n      associated with congenital heart disease and its treatment. Measuring cerebral oxygenation\n      is a promising non-invasive way of cerebral monitoring in a neonatal intensive care unit.\n      The importance of cerebral monitoring in neonates with congenital heart problems at risk of\n      developing neurological complications is increasingly recognized. In this way the most\n      vulnerable moments for the newborn brain can be detected and ,if possible, lead to change in\n      (timing of) treatment.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [],
    clinical_results: 'No' },
  { nct_id: 'NCT02131675',
    conditions: [ 'Type 1 Diabetes Mellitus' ],
    overall_status: 'Completed',
    summary: 'Background Type 1 diabetes is characterized by pancreatic beta-cell destruction and an\n      inability to synthesize insulin.  Connecting peptide (C-peptide) is formed from the same\n      precursor as insulin and is produced in equimolar amounts as insulin.  There are several\n      clinical trials currently being performed to explore the possibility of beta-cell\n      preservation or regeneration.  Most children are not eligible for these trials because it is\n      often presumed that C-peptide levels will decrease and become undetectable after years of\n      having type 1 diabetes.  Several studies in the adult population have demonstrated that\n      C-peptide may remain measureable in patients who have had diabetes for up to 50 years after\n      diagnosis.  Recently, it was demonstrated that 10% of adult patients who have had type 1\n      diabetes for 31-40 years have measureable levels of serum C-peptide if measured with an\n      ultrasensitive assay.  The levels were lower in patients who had diabetes for a longer time.\n       This pattern was also demonstrated in the Diabetes Control and Complications Trial (DCCT)\n      and NHANES trial.  No studies have been performed exclusively in pediatric patients\n      Hypothesis The investigators hypothesize that C-peptide should be detectable in the sera of\n      pediatric patients who have had type 1 diabetes for greater than 1 year and as far out as >\n      20 years after diagnosis.  The investigators also hypothesize that since their patient\n      population has had diabetes for less time as compared to adults, the levels of C-peptide\n      should be higher than reported for adults and that a greater proportion of patients in the\n      pediatric population will have detectable C-peptide levels as compared to adults.',
    primary_outcomes: [ [Object] ],
    secondary_outcomes: [ [Object], [Object], [Object], [Object] ],
    clinical_results: 'No' } ]
--------------------------  Response END ---------------------------------
[90mGET /search/9397e43c-47e2-2a45-3b30-c8f945d9de42 [32m200 [90m35ms[0m
[90mGET / [32m200 [90m30ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m194ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m2ms[0m
[90mGET / [32m200 [90m34ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUsername{ exists: true, value: 'GOPI' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM; ctcUsername=GOPI; ctcUser_id=1000002; ctcToken=a7bff5a2c2d3a6a1dc7e959b8995fb2f43b38d9367a1918cbbdb59ffd5d15f72
Returining for cookieName ctcUser_id{ exists: true, value: '1000002' }
{ exists: true, value: 'GOPI' }
{ exists: true, value: '1000002' }
[90mGET /catalog [32m200 [90m110ms - 9.83kb[0m
fetching data for  { userId: '1000002' }
-----------------------------  Response ---------------------------------
[ { _id: 546e8f7d07844582fd1395e5,
    userId: 1000002,
    collectionName: 'collection-2' },
  { _id: 546e8f8b07844582fd1395e6,
    userId: 1000002,
    collectionName: 'collection-1' },
  { _id: 546f3f5c07844582fd1395ed,
    userId: 1000002,
    collectionName: 'collection-18' },
  { _id: 546f3f6e07844582fd1395f3,
    userId: 1000002,
    collectionName: 'collection-24' },
  { _id: 546f3f7007844582fd1395f4,
    userId: 1000002,
    collectionName: 'collection-25' } ]
--------------------------  Response END ---------------------------------
[90mGET /collection/1000002 [32m200 [90m3ms[0m
[90mGET /signout [32m200 [90m120ms - 5.77kb[0m
[90mGET / [32m200 [90m30ms - 3kb[0m
[90mGET / [32m200 [90m31ms - 3kb[0m
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUsername{ exists: false, value: '' }
Headers.cookies _ga=GA1.1.751950638.1406051789; remember_token=8bf646415970d3f7d63a2d9b05ca02a0d74408a9; express.sid=s%3AlKHrf-tOgHYIu1tc8bVH394jNeUSlhg0.8sikaj7a2TSwnxhWM1H3Vu5bg58pIkZ07LoSzz6bUhM
Returining for cookieName ctcUser_id{ exists: false, value: '' }
[90mGET /catalog [32m200 [90m60ms - 5.77kb[0m
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T04:08:26.459Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T04:16:05.078Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T13:51:14.074Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T14:11:18.721Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T14:12:38.616Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T14:16:19.511Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T14:19:47.847Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T14:20:25.140Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:17:03.532Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:22:14.060Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:24:02.576Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:39:29.010Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:40:30.505Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:42:15.623Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:47:34.063Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:48:14.371Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T15:49:32.868Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:07:48.050Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:09:33.174Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:10:49.326Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:13:22.583Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:13:56.698Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:15:36.445Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:16:47.388Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:18:02.743Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:25:15.364Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:28:50.870Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-28T17:31:27.258Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T03:47:52.689Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T04:24:31.763Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T04:32:25.556Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T15:13:23.922Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T15:14:04.563Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T18:36:07.157Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T18:39:08.878Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-29T21:47:23.884Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T14:18:49.943Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T14:26:45.191Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T14:27:44.008Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T14:28:06.596Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T14:31:54.265Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T14:33:14.661Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-11-30T15:48:45.614Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-01T00:17:10.370Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-03T13:12:14.698Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-03T18:47:43.878Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-06T14:12:42.758Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-06T15:02:20.973Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-06T15:04:21.449Z"}
{"level":"info","message":"Express server listening on port 9801","timestamp":"2014-12-07T21:07:04.160Z"}
